Prognostic biomarkers in individuals with prevalent coronary heart disease

Disease Markers

Volumn 26, Issue 5-6, 2009, Pages 265-271

  Halim, Sharif A ^a   Newby, L Kristin ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biomarkers; Coronary heart disease; Prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CYSTATIN C; GROWTH DIFFERENTIATION FACTOR 15; PHOSPHOLIPASE A2; TROPONIN I; TROPONIN T;

ACUTE CORONARY SYNDROME; BODY FLUID; EPIDEMIOLOGICAL DATA; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; UNITED STATES;

EID: 70349909387     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.3233/DMA-2009-0645     Document Type: Review

References (50)

1. D. Lloyd-Jones, R. Adams, M. Carnethon et al., Heart disease and stroke statistics 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Circulation 119 (2009), e21-e181.
2. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N Engl J Med 339 (1998), 1349-1357.
3. Heart Outcomes Prevention Evaluation Study Investigators, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients, N Engl J Med 342 (2000), 145-153.
4. Antithrombotic Trialists Collaboration, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients, BMJ 324 (2002), 71-86.
5. CAPRIE Steering Committee, A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE), Lancet 348 (1996), 1329-1339.
6. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators, Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, N Engl J Med 345 (2001), 494-502.
7. F.S. Apple, A.H. Wu, J. Mair, J. Ravkilde, M. Panteghini, J. Tate, F. Pagani, R.H. Christenson, M. Mockel, O. Danne et al., for the Committee on Standardization of Markers of Cardiac Damage of the IFCC, Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome, Clin Chem 51 (2005), 810-824.
8. G.S. Ginsburg, M. Donahue and L.K. Newby, Prospects for personalized cardiovascular medicine: the impact of genomics, J Am Coll Cardiol 46 (2005), 1615-1627. (Pubitemid 41531613)
9. D.A. Morrow, C.P.Cannon, R.L. Jesse, L.K. Newby, J. Ravkilde, A.B. Storrow, A.H.B. Wu and R.H. Christenson, National Academy of Clinical Biochemistry LaboratoryMedicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes, Circulation 115 (2007), e356-375.
10. C. Heeschen, S. Dimmeler, C.W. Hamm, S. Fichtlscherer, M.L. Simoons and A.M. Zeiher, for the CAPTURE Investigators. Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis, J Am Coll Cardiol 45 (2005), 229-237.
11. M.S. Sabatine, D.A. Morrow, J.A. de Lemos, C.M. Gibson, S.A. Murphy, N. Rifai, C. McCabe, E.M. Antman, C.P. Cannon and E. Braunwald, Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide, Circulation 105 (2002), 1760-1763.
12. S. Baldus et al., Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes, Circulation 108 (2003), 1440-1445. (Pubitemid 37176448)
13. C.M. Westerhout, Y. Fu, M.S. Lauer, S. James, P.W. Armstrong, E. Al-Hattab, R.M. Califf, M.L. Simoons, L. Wallentin and E. Boersma, for the GUSTO-IV ACS Trial Investigators, Short- and long-term risk stratification in acute coronary syndromes: the added value of quantitative ST-segment depression and multiple biomarkers, J Am Coll Cardiol 48 (2006), 939-947.
14. D.A. Morrow, E.M. Antman, M. Tanasijevic, N. Rifai, J.A. de Lemos, C.H. McCabe, C.P. Cannon and E. Braunwald, Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy, J Am Coll Cardiol 36 (2000), 1812-1817.
15. D.A. Morrow, C.P. Cannon, N. Rifai, M.J. Frey, R. Vicari, N. Lakkis, D.H. Robertson, D.A. Hille, P.T. DeLucca, P.M. DiBattiste et al., Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial, JAMA 286 (2001), 2405-2412.
16. L.K. Newby, E.M. Ohman, R.H. Christenson, D.J. Moliterno, R.A. Harrington, H.D. White, P.W. Armstrong, F. Van de Werf, M. Pfisterer, V. Hasselblad et al., Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy, Circulation 103 (2001), 2891-2896.
17. C. Heeschen, C.W. Hamm, B. Goldmann, A. Deu, L. Langebrink and H.D. White, for the PRISM Study Investigators. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban, Lancet 354 (1999), 1757-1762.
18. R. Ross, Atherosclerosis: an inflammatory disease, N Engl J Med 340 (1999), 115-126.
19. P.M. Ridker, N. Rifai, M.A. Pfeffer, F.M. Sacks, L.A. Moye, S. Goldman, G.C. Flaker and E. Braunwald, for the Cholesterol and Recurrent Events (CARE) investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels, Circulation 98 (1998), 839-844.
20. P.M. Ridker, N. Rifai, M.A. Pfeffer, F. Sacks and E. Braunwald, for the Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein, Circulation 100 (1999), 230-235.
21. P.M. Ridker, N. Rifai, M. Clearfield, J.R. Downs, S.E. Weis, J.S. Miles and A.M. Gotto, for the Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events, N Engl J Med 344 (2001), 1959-1965.
22. M.A. Albert, E. Danielson, N. Rifai and P.M. Ridker, Effect of statin therapy of C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study, JAMA 286 (2001), 64-70.
23. P.M. Ridker, N. Rifai and S.P. Lowenthal, Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia, Circulation 103 (2001), 1191-1193.
24. I. Jialal, C. Stein, D. Balis, S.M. Grundy, B. Adams-Huet and S. Deveraj, Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels, Circulation 103 (2001), 1933-1935.
25. S.E. Nissen, E.M. Tuzcu, P. Schoenhagen, B.G. Brown, P. Ganz, R.A. Vogel, T. Crowe, G. Howard, C.J. Cooper, B. Brodie, C.L. Grines, A.N. DeMaria, REVERSAL Investigators, Effect of intensive compared with moderate lipidlowering therapy on progression of coronary atherosclerosis: a randomized controlled trial, JAMA 291 (2004), 1071-1080. (Pubitemid 38541684)
26. P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr., J.J. Kastelein, W. Koenig, P. Libby, A.J. Lorenzatti, J.G. MacFadyen, B.G. Nordestgaard, J. Shepherd, J.T. Willerson and R.J. Glynn, JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein, N Engl J Med 359 (2008), 2195-2207.
27. E. Zouridakis, P. Avanzas, R. Arroyo-Espliguero, S. Fredericks and J.C. Kaski, Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris, Circulation 110 (2004), 1747-1753. (Pubitemid 39299216)
28. J.A. de Lemos, D.A. Morrow, M.A. Blazing, P. Jarolim, S.D. Wiviott, M.S. Sabatine, R.M. Califf and E. Braunwald, Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial, J Am Coll Cardiol 50 (2007), 2117-2124.
29. G. Ndrepepa, S. Braun, K. Niemöller, J. Mehilli, N. von Beckerath, O. von Beckerath, W. Vogt, A. Schömig and A. Kastrati, Prognostic value of N-terminal pro-brain natriuretic peptide in patients with chronic stable angina, Circulation 112 (2005), 2102-2107. (Pubitemid 41475802)
30. C. Kragelund, B. Grønning, L. Køber, P. Hildebrandt and R. Steffensen, N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease, N Engl J Med 352 (2005), 666-675. (Pubitemid 40239214)
31. D.A. Brown, S.N. Breit, J. Buring, W.D. Fairlie, A.R. Bauskin, T. Liu and P.M. Ridker, Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study, Lancet 359 (2002), 2159-2163.
32. T. Kempf, E. Björklund, S. Olofsson, B. Lindahl, T. Allhoff, T. Peter, J. Tongers, K.C. Wollert and L. Wallentin, Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction, Eur Heart J 28 (2007), 2858-2865. (Pubitemid 350233034)
33. K.C. Wollert, T. Kempf, T. Peter, S. Olofsson, S. James, N. Johnston, B. Lindahl, R. Horn-Wichmann, G. Brabant, M.L. Simoons, P.W. Armstrong, R.M. Califf, H. Drexler and L. Wallentin, Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome, Circulation 115 (2007), 962-971. (Pubitemid 46328289)
34. K.C. Wollert, T. Kempf, B. Lagerqvist, B. Lindahl, S. Olofsson, T. Allhoff, T. Peter, A. Siegbahn, P. Venge, H. Drexler and L. Wallentin, Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome, Circulation 116 (2007), 1540-1548.
35. M.J. Sarnak, A.S. Levey, A.C. Schoolwerth, J. Coresh, B. Culleton, L.L. Hamm et al., Kidney disease as a risk factor for development of cardiovascular disease, Circulation 108 (2003), 2154-2169.
36. J.F. Mann, H.C. Gerstein, J. Pogue, J. Bosch and S. Yusuf, Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial, Ann Intern Med 134 (2001), 629-636.
37. M. Abrahamson, A. Grubb, I. Olafsson and A. Lundwall, Molecular cloning and sequence analysis of cDNA coding for the precursor of the human cysteine proteinase inhibitor cystatin C, FEBS Lett 216 (1987), 229-233.
38. S. Herget-Rosenthal, S. Trabold, F. Pietruck, M. Holtmann, T. Philipp and A. Kribben, Cystatin C: efficacy as screening test for reduced glomerular filtration rate, Am J Nephrol 20 (2000), 97-102.
39. M.G. Shlipak, M.J. Sarnak, R. Katz, L.F. Fried, S.L. Seliger, A.B. Newman, D.S. Siscovick and C. Stehman-Breen, Cystatin C and the risk of death and cardiovascular events among elderly persons, N Engl J Med 352 (2005), 2049-2060. (Pubitemid 40664306)
40. T. Jernberg, B. Lindahl, S. James, A. Larsson, L.O. Hansson and L. Wallentin, Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome, Circulation 110 (2004), 2342-2348. (Pubitemid 39407337)
41. W. Koenig, D. Twardella, H. Brenner and D. Rothenbacher, Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate, Clin Chem 51 (2005), 321-327.
42. M.G. Shlipak, J.H. Ix, K. Bibbins-Domingo, F. Lin and M.A. Whooley, Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study, Am J Med 121 (2008), 50-57.
43. G. Luc, J.M. Bard, C. Lesueur, D. Arveiler, A. Evans, P. Amouyel, J. Ferrieres, I. Juhan-Vague, J.C. Fruchart and P. Ducimetiere, PRIME Study Group. Plasma cystatin-C and development of coronary heart disease: The PRIME Study, Atherosclerosis 185 (2006), 375-380. (Pubitemid 43306752)
44. J.L. Anderson, Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention, Am J Cardiol 101 (2008), 23F-33F.
45. M.A. Corson, P.H. Jones and M.H. Davidson, Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker, Am J Cardiol 101 (2008), 41F-50F.
46. M.H. Davidson, M.A. Corson, M.J. Alberts, J.L. Anderson, P.B. Gorelick, P.H. Jones, A. Lerman, J.P. McConnell and H.S. Weintraub, Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines, Am J Cardiol 101 (2008), 51F-57F.
47. R.L. Wilensky, Y. Shi, E.R. Mohler 3rd, D. Hamamdzic, M.E. Burgert, J. Li, A. Postle, R.S. Fenning, J.G. Bollinger, B.E. Hoffman, D.J. Pelchovitz, J. Yang, R.C. Mirabile, C.L. Webb, L. Zhang, P. Zhang, M.H. Gelb, M.C. Walker, A. Zalewski and C.H. Macphee, Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development, Nat Med 14 (2008), 1059-1066.
48. E.S. Brilakis, A. Khera, B. Saeed, S. Banerjee, D.K. McGuire, S.A. Murphy and J.A. de Lemos, Association mass and activity with coronary and aortic atherosclerosis: findings from the Dallas Heart Study, Clin Chem 54 (2008), 1975-1981.
49. P.W. Serruys, H.M. García-García, P. Buszman, P. Erne, S. Verheye, M. Aschermann, H. Duckers, O. Bleie, D. Dudek, H.E. Bøtker, C. von Birgelen, D. D'Amico, T. Hutchinson, A. Zambanini, F. Mastik, G.A. van Es, A.F. van der Steen, D.G. Vince, P. Ganz, C.W. Hamm, W. Wijns and A. Zalewski, Integrated Biomarker and Imaging Study-2 Investigators. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque, Circulation 118 (2008), 1172-1182.
50. E.R. Mohler 3rd, C.M. Ballantyne, H.M. Davidson, M. Hanefeld, L.M. Ruilope, J.L. Johnson and A. Zalewski, Darapladib Investigators, The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study, J Am Coll Cardiol 51 (2008), 1632-1641.